Close

Acorda Therapeutics (ACOR) Tops Q2 EPS by 7c

August 1, 2011 6:50 AM EDT
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of $0.19, $0.07 better than the analyst estimate of $0.12. Revenue for the quarter came in at $65.28 million versus the consensus estimate of $66.29 million.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings